Mount Arlington, New Jersey

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

This Phase III study is designed as a randomized, double-blinded, placebo- controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population. Study visits: Screening, Day 1 (Baseline), Week 4, Week 12, Week 24, Week 48, and Week 72. Compensation: Contact to Find out More 888-885-0382 [www.cognitetrial.com](http://www.cognitetrial.com/)